Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC <li /> <str ...

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today with ...

Clarivate identifies eleven potential blockbuster and transformative drugs in annual Drugs to Watch report: London, UK Friday, January 10, 2025, 14:00 Hrs [IST] Clarivate Plc, a l ...

Tens of millions of pounds in investment is being provided by the group of firms which includes AstraZenecaa and Pfizer ...

Middle East and Asia Injectable Drugs market 2025 To achieve a therapeutic effect in humans and animals, drug delivery is the method of delivering a Pharmaceutical compound. Mr. Shah Coherent Market ...

Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

Ramos, previously Pfizer's senior vice president and global head of BioTherapeutics R&D, has been appointed to the board of ...

On Tuesday, January 7, the FDA announced it would now be requiring GSK and Pfizer’s RSV vaccines to hold warnings of a risk ...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ...